Newswire (Published: Tuesday, March 21, 2017, Received: Friday, March 17, 2017, 6:12:54 AM CDT)

Word Count: 423

New Prostate Cancer Study Findings Have Been Reported by Researchers at University of California (Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?)

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating in San Francisco, California, by NewsRx journalists, research stated, "Active surveillance has become the recommended management strategy for most patients with low-risk prostate cancer (PCa), but whether surveillance criteria can be expanded without compromising oncologic outcomes is a matter of debate. Whereas there is essentially uniform consensus that those with low-risk disease can be safely managed with AS, those with intermediate-risk disease, younger men and African-American men are often excluded."

The news reporters obtained a quote from the research from the University of California, "Outcome data for intermediate-risk patients managed by active surveillance demonstrate acceptable oncologic outcomes, but there is also evidence that such patients have higher rates of progression, adverse disease and metastatic disease. Studies evaluating the utility of quantitative Gleason grade, the use of biomarkers and multiparametric MRI are emerging and are likely to refine risk assessment. Literature describing the effects of young age on outcomes is lacking, but early data appear promising. Data on African-American men show varied results that are sometimes contradictory and further investigation is needed to elucidate the impact of race, independent of socioeconomic status."

According to the news reporters, the research concluded: "Patients with intermediate-risk PCa should not be excluded from active surveillance based on any single, borderline criterion; rather, treatment decisions should be based on the full clinical picture, and may be further refined by patient characteristics and adjunctive tools."

For more information on this research see: Management of intermediate-risk prostate cancer with active surveillance: never or sometimes? Current Opinion In Urology, 2017;():. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion In Urology - journals.lww.com/co-urology/pages/default.aspx)

Our news correspondents report that additional information may be obtained by contacting S. Masic, Dept. of Urology, UCSF - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States. Additional authors for this research include S.L. Washington and P.R Carroll (see also Oncology - Prostate Cancer).

Keywords for this news article include: Oncology, California, Epidemiology, San Francisco, United States, Prostate Cancer, Prostatic Neoplasms, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

University of California
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
University of California San Francisco
Wolters Kluwer N.V.

Places

Central America
North America
United States
Americas
California
San Francisco

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
            Urology